The combination of metabonomics and pharmacokinetics model to establish the individualized medication model and clinical intervention study of linezolid in renal insufficiency patients

Study on dynamic prediction of the effect of linezolid on platelets in renal insufficiency patients based on the combined model of metabonomics and pharmacokinetics

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048473

Enrollment

Unknown

Registered

2021-07-09

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal insufficiency

Interventions

intervention group:Individualized dosage

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients with renal insufficiency and CRRT admitted to the ICU of our hospital; 2. Choose linezolid for empirical or targeted anti-infective therapy according to clinical needs; 3. The steady-state plasma trough and metabolite concentrations of linezolid were determined.

Exclusion criteria

Exclusion criteria: 1. Allergic reaction after using linezolid; 2. The blood trough concentration and metabolite concentration of linezolid were not measured or not measured at the specified time point; 3. Incomplete index inspection or record before and after medication; 4. The use of linezolid for 400x10^9/L) of platelet value before use of linezolid.

Design outcomes

Primary

Measure	Time frame
Thrombocytopenia;	—

Countries

China

Contacts

Public ContactTang Lian

The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital

tanglian716@aliyun.com+86 15250491039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026